| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Common Stock | Options Exercise | $245K | +28.3K | +26.92% | $8.66* | 133K | Jan 5, 2022 | Direct | |
| transaction | NBIX | Common Stock | Sale | -$2.42M | -28.3K | -21.21% | $85.50 | 105K | Jan 5, 2022 | Direct | F1, F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Non-Qualified Stock Option | Options Exercise | -$245K | -28.3K | -100% | $8.66* | 0 | Jan 5, 2022 | Common Stock | 28.3K | $8.66 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. |
| F2 | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.11 to $87.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F3 | Includes an aggregate of 216 shares purchased on February 26, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| F4 | Option granted January 12, 2012 and vested monthly over four years. |